ReviewStem cells translational medicine2016
Strategies and Challenges to Myocardial Replacement Therapy.
Review in Stem cells translational medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 44 citations in OpenAlex.
- An overview of recent flexible- and soft-biomaterial applications in myocardial infarction and other cardiovascular diseases.Materials today. Bio · 2026Review
- Stem Cell Therapy in Ischemic Heart Failure.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2025Review
- Review
- Non-human primate studies for cardiomyocyte transplantation-ready for translation?Frontiers in pharmacology · 2024Review
- A micro-LED array based platform for spatio-temporal optogenetic control of various cardiac models.Scientific reports · 2023Article
- Harnessing conserved signaling and metabolic pathways to enhance the maturation of functional engineered tissues.NPJ Regenerative medicine · 2022Review
- Possible Treatment of Myocardial Infarct Based on Tissue Engineering Using a Cellularized Solid Collagen Scaffold Functionalized with Arg-Glyc-Asp (RGD) Peptide.International journal of molecular sciences · 2021Review
- A New Role for Extracellular Vesicles in Cardiac Tissue Engineering and Regenerative Medicine.Advanced nanobiomed research · 2021Article
- Nanotechnology in cardiac stem cell therapy: cell modulation, imaging and gene delivery.RSC advances · 2021Review
- Synthesis and characterization of peptide conjugated human serum albumin nanoparticles for targeted cardiac uptake and drug delivery.PloS one · 2021Article
- Cardiac Stem Cell-Loaded Delivery Systems: A New Challenge for Myocardial Tissue Regeneration.International journal of molecular sciences · 2020Review
- Three-dimensional scaffold-free microtissues engineered for cardiac repair.Journal of materials chemistry. B · 2020Review
- Optimizing Anisotropic Polyurethane Scaffolds to Mechanically Match with Native Myocardium.ACS biomaterials science & engineering · 2020Article
- N-cadherin overexpression enhances the reparative potency of human-induced pluripotent stem cell-derived cardiac myocytes in infarcted mouse hearts.Cardiovascular research · 2020Article
- A tissue-engineered scale model of the heart ventricle.Nature biomedical engineering · 2018Article
- 3D bioprinting for cardiovascular regeneration and pharmacology.Advanced drug delivery reviews · 2018Review
- Modeling Human Cardiac Hypertrophy in Stem Cell-Derived Cardiomyocytes.Stem cell reports · 2018Article
- An Injectable Oxygen Release System to Augment Cell Survival and Promote Cardiac Repair Following Myocardial Infarction.Scientific reports · 2018Article
- The current status and future of cardiac stem/progenitor cell therapy for congenital heart defects from diabetic pregnancy.Pediatric research · 2018Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
unlabelledCardiovascular diseases account for the majority of deaths globally and are a significant drain on economic resources. Although heart transplants and left-ventricle assist devices are the solution for some, the best chance for many patients who suffer because of a myocardial infarction, heart failure, or a congenital heart disease may be cell-based regenerative therapies. Such therapies can be divided into two categories: the application of a cell suspension and the implantation of an in vitro engineered tissue construct to the damaged area of the heart. Both strategies have their advantages and challenges, and in this review, we discuss the current state of the art in myocardial regeneration, the challenges to success, and the future direction of the field. SIGNIFICANCE: This article outlines the advantages and limitations of the cell injection and patch approaches to cardiac regenerative therapy. If the field is to move forward, some fundamental questions require answers, including the limitations to the use of animal models for human cell-transplantation studies; the best way to measure success in terms of functional improvements, histological integration, electrical coupling, and arrhythmias; and where the cells should be applied for maximal benefit-the epicardium or the myocardium.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.